Tuesday 21 July | Satellite Sessions

TUSA01  Computational Models of HIV/AIDS: Sharing New Tools and Ideas
Non-Commercial Satellite
Venue: Room 109
Date: Tuesday 21 July
Time: 07:00-08:30
Organizer: Institute for Disease Modeling, University of Washington, BC Centre for Excellence in HIV/AIDS, Avenir Health, and Imperial College London

Join us in a conversation about how population level computational models can use real world programmatic and research data to estimate the impact of health policy.

Welcome

Decision support for policy

Lessons from synthesising multiple mathematical models
J.Eaton, Imperial College London, HIV Modelling Consortium, United Kingdom

Modeling cost and optimization of care
R.Barnabas, University of Washington, United States

Statistics and modeling
V.Lima, British Columbia Centre for Excellence in HIV/AIDS, Canada

Approaches for modeling heterogeneous access to care
A.Bershteyn, Institute for Disease Modeling, United States

Introducing EMOD: a conversation with model developers
D.Klein, Institute for Disease Modeling, United States; J.Bioloow, Institute for Disease Modeling, United States; D.Bridgewater, Institute for Disease Modeling, United States; B.Lorton, Institute for Disease Modeling, United States; C.Lorton, Institute for Disease Modeling, United States; K.Oishi, Institute for Disease Modeling, United States; C.Selinger, Institute for Disease Modeling, United States; J.Gould, Institute for Disease Modeling, United States; C.Wissell, Institute for Disease Modeling, United States; C.Thurley, Institute for Disease Modeling, United States; A.Bershteyn, Institute for Disease Modeling, United States

TUSA02  New treatments and new trends in the management of HIV-HCV coinfection
Major Industry Sponsor Satellite
Venue: Room 211-214
Date: Tuesday 21 July
Time: 07:00-08:30
Organizer: MSD

Welcome
C.Coopcr, University of Ottawa, Canada

Are coinfected patients a special population?
C.Coopcr, University of Ottawa, Canada

Emerging data in coinfected patients - new HCV DAAs
S.Shafran, University of Alberta Hospital, Canada

Drug-drug interactions and other considerations for successful HCV treatment
P.Giguere, Ottawa Hospital, Canada

Q&A

TUSA03  The CTN Silver Anniversary – Triumphs and Future Goals
Non-Commercial Satellite
Venue: Room 118-120
Date: Tuesday 21 July
Time: 18:30-20:30
Organizer: CIHR Canadian HIV Trials Network (CTN)

This session will bring together delegates to mark the 25th anniversary of the CIHR Canadian HIV Trials Network (CTN). Established in 1990 by the Canadian government, the CTN is an innovative partnership of clinical investigators, physicians, nurses, people living with HIV, and others that facilitate HIV clinical trials of the highest scientific and ethical standards. The session will highlight the history and vision of the CTN and showcase a number of collaborations and CTN research projects in the areas of clinical management science, co-infections and concurrent diseases, prevention and key populations and vaccines and immunotherapies. Since its inception, the CTN has built a successful infrastructure that ensures Canadian HIV researchers collaborate locally and internationally to improve health outcomes, train the next generation of postdoctoral fellows, and lead cutting edge research in HIV and related health conditions. A reception will follow presentations.

Introductory Remarks
A.Anis, CIHR Canadian HIV Trials Network; University of British Columbia, Canada

What/who is the CTN and how has it evolved
A.Anis, CIHR Canadian HIV Trials Network; University of British Columbia, Canada; S.Walmsley, CIHR Canadian HIV Trials Network; University of Toronto, Canada; M.Klein, McGill University, Canada

Remarks from CIHR
M.Ouellette, , Canada; M.Ouellette, , Canada; M.Ouellette, , Canada

Remarks from founding Co-director
D.Tan, St. Michael's Hospital, Canada; M.Hull, British Columbia Centre for Excellence in HIV/AIDS, Canada

CTN and the community
S.Margolese, CIHR Canadian HIV Trials Network, Canada

Panel on CTN international collaborations
S.Walmsley, CIHR Canadian HIV Trials Network; University of Toronto, Canada; J.Molina, Saint-Louis Hospital, France; J.Rockstroh, Bonn University Hospital, Germany; R.Gulick, Weill Medical College, Cornell University, United States; D.Margolis, UNC Chapel Hill, United States

Canadian Research Partners
S.Rourke, REACH 2.0, OHTN, Canada; C.Bunting, CANFAR, Canada

Concluding Remarks
A.Anis, CIHR Canadian HIV Trials Network; University of British Columbia, Canada

Reception

TUSA04  Expanding Access to Diagnostic Testing in Resource-Limited Settings
Corporate Satellite
Venue: Room 121-122
Date: Tuesday 21 July
Time: 18:30-20:30
Organizer: BD Biosciences

The BD FACSPresto™ Near-Patient CD4 Counter* provides absolute and percentage results of CD4 T lymphocytes and total hemoglobin (Hb) concentration in whole blood samples. The small, portable system fits the needs of resource-limited settings and handles extreme environmental conditions. The BD FACSPresto can be operated using a rechargeable battery, without a conventional electricity supply.

BD Biosciences will review the BD FACSPresto CD4 and Hb data produced during multisite clinical trials and will preview the BD FACSVia™ flow cytometer (product under development). This system will provide greater access to flow cytometry, simplifying adoption through use of anthropology in software design, and by miniaturization of almost all aspects of system electronics and fluidics. Besides CD4 enumeration, the BD FACSVia will provide capabilities for monitoring immune status using methods tailored to individual laboratory requirements.

* (BD FACSPresto is CE-marked according to the In Vitro Diagnostic Directive 98/79/EC, Annex III; not approved in Canada.)
The role of IFN in driving HIV-1 pathogenesis is controversial. In order to control HIV infection, should we block, or rather induce, Type I IFN-mediated responses? The ANRS meeting will bring together L.J. Montaner, F. Kirchhoff, N. Sandler Utay, M. Muller-Trutwin, R-P Sekaly, A. Hosmalin, D. Scott-Algara. and Françoise Barre-Sinoussi. The role of IFN and the impact of IFN-mediated responses on viral replication, restriction factors, innate effectors, immune activation and disease progression, will be addressed. The goal is to discuss strategies to harness innate immunity for advancing cure strategies to control HIV infection.

Opening
J. Montaner, The Wistar Institute, United States

Introduction
F. Barré-Sinoussi, Institut Pasteur, France

Type I IFN in HIV Cure beyond ART
L. Montaner, The Wistar Institute, United States

Lessons from the Virus-Host Interactions Front
F. Kirchhoff, University of Ulm, Germany

Contrasting Lessons from Non-Human Primate Models
N. Sandler Utay, University of Texas Medical Branch, United States

The Secret Life of Interferon-alpha
M. Muller-Trutwin, Institut Pasteur, France

Discussion and Floor Interventions
A. Hosmalin, Cochin Institute, France

Duality of Interferons in Modulating Immune Responses
R. Sekaly, Case Western Reserve University, United States

Type I IFN: A Dual-faced Genius to Charm
A. Hosmalin, Cochin Institute, France

Type I Interferon and Control of HIV and AIDS
D. Scott-Algara, Institut Pasteur, France

Discussion and Floor Interventions
F. Barré-Sinoussi, Institut Pasteur, France

Towards an HIV Cure: Canadian Global Stakeholder’s Engagement Workshop
J. Nkengasong, Centers for Disease Control USA, United States

Opening
J. Nkengasong, Centers for Disease Control USA, United States

Welcome and introduction
L. Montaner, The Wistar Institute, United States

Models of Specific Populations Engagement - Canada & Globally
R. Masching, Canadian Aboriginal AIDS Network, Canada; T. Wangari, Women’s Health in Women’s Hands CHC, Canada; A. Lambert, TB/HIV Care Association, South Africa

Key Populations in HIV Cure Research: The Role of the Community
R. Reinhard, Institut de Recherches Clinique de Montreal, Canada; N. Chomont, University of Montreal, Canada; J. Auerbach, University of California, San Francisco, United States; B. Spire, INSERM, France

Looking Towards 2016
M. Sharp, HIV Education & Advocacy Consultant, United States

Keeping the Health of Patients in the Green Zone - Problems and Solutions for Each Decade of Age Living with HIV
K. Squires, Thomas Jefferson University, United States

50 years old and counting
T. Mills, Men’s Health Foundation, United States

60 years old: a different picture
J. Appelbaum, Florida State University, United States

75 years old and pulling it off
K. Squires, Thomas Jefferson University, United States

Inflammaging: the root of all evils?
J. Appelbaum, Florida State University, United States

Welcome and opening
K. Squires, Thomas Jefferson University, United States

50 years old and counting
T. Mills, Men’s health foundation, United States

60 years old: a different picture
J. Appelbaum, Florida State University, United States

75 years old and pulling it off
K. Squires, Thomas Jefferson University, United States

Inflammaging: the root of all evils?
J. Appelbaum, Florida State University, United States

Back to the 30’s: preserving the health capital
G. Guaraldi, Azienda Ospedaliero-Universitaria Policlinico di Modena, Infectious Disease Clinic, Italy

Q&A